Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Obesity
Biotech
BioAge brings in $198M from IPO as obesity biotech joins Nasdaq
BioAge Labs is bringing in almost $200 million via its Nasdaq IPO, with proceeds earmarked for taking its obesity drug further into clinical trials.
James Waldron
Sep 26, 2024 4:44am
BioAge eyes $180M from IPO, private placement for obesity trials
Sep 25, 2024 7:55am
Metsera GLP-1 data slice reveals 7.5% weight loss at 36 days
Sep 24, 2024 7:00am
Sanofi makes $27M equity investment in Ventyx
Sep 23, 2024 11:24am
Novo obesity prospect linked to ‘neuropsychiatric side effects’
Sep 20, 2024 10:25am
Roche hopes obesity drug will show 25% weight loss one day
Sep 11, 2024 11:45am